Treated participants’ risk of heart attack or stroke dropped by 58%.
The trial: Mesoblast has now tested the therapy, called “rexlemestrocel-L,” in a double-blind, randomized phase 3 trial, which it says is the largest trial of a cell therapy in patients with chronic heart failure. The results have been published in the Journal of the American College of Cardiology.
During this trial, 537 patients with HFrEF received an injection of about 150 million MPCs straight into the muscular tissue of their hearts — or a sham treatment with no injection. All of the participants were also receiving standard heart failure treatment at the time of the trial.
Comments are closed.